Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes

References

• Xia MQ, Tone M, Packman L, . Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 1991;21:1677–1684.
   PubMed Web of Science ®Google Scholar
• Xia MQ, Hale G, Lifely MR, . Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293(Pt 3):633–640.
   PubMed Web of Science ®Google Scholar
• Hale G, Rye PD, Warford A, . The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. J Reprod Immunol 1993;23:189–205.
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E, . Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185–191.
   PubMed Web of Science ®Google Scholar
• Hirst CL, Pace A, Pickersgill TP, . Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255:231–238.
   PubMed Web of Science ®Google Scholar
• Jones JL, Coles AJ. Campath-1H treatment of multiple sclerosis. Neurodegener Dis 2008;5:27–31.
   PubMed Web of Science ®Google Scholar
• Hale G, Jacobs P, Wood L, . CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000;26:69–76.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Masuyama J, Sohma Y, . CD52 is a novel costimulatory molecule for induction of CD4 + regulatory T cells. Clin Immunol 2006;120 :247–259.
   PubMed Web of Science ®Google Scholar
• Bloom DD, Chang Z, Fechner JH, . CD4 + CD25 + FOXP3 + regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008;8:793–802.
   PubMed Web of Science ®Google Scholar
• Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, . CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma 2007;48:2424–2436.
   PubMed Web of Science ®Google Scholar
• Zent CS, Secreto CR, LaPlant BR, . Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008;32:1849–1856.
   PubMed Web of Science ®Google Scholar
• Golay J, Manganini M, Rambaldi A, . Effect of alemtuzumab on neoplastic B cells. Haematologica 2004;89:1476–1483.
   PubMed Web of Science ®Google Scholar
• Hu Y, Turner MJ, Shields J, . Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128:260–270.
   PubMed Web of Science ®Google Scholar
• Siders WM, Shields J, Garron C, . Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma 2010;51:1293–1304.
   PubMed Web of Science ®Google Scholar
• Rowan W, Tite J, Topley P, . Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998;95:427–436.
   PubMed Web of Science ®Google Scholar
• Nuckel H, Frey UH, Roth A, . Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 2005;514:217–224.
   PubMed Web of Science ®Google Scholar
• Mone AP, Cheney C, Banks AL, . Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006;20:272–279.
   PubMed Web of Science ®Google Scholar
• Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004;83:634–645.
   PubMed Web of Science ®Google Scholar
• Kim KM, Yoshimura T, Watanabe H, . Growth regulation of a human mature B cell line, B104, by anti-IgM and anti-IgD antibodies. J Immunol 1991;146:819–825.
   PubMed Web of Science ®Google Scholar
• Siebenlist U, Hennighausen L, Battey J, . Chromatin structure and protein binding in the putative regulatory region of the c-myc gene in Burkitt lymphoma. Cell 1984;37:381–391.
   PubMed Web of Science ®Google Scholar
• Nacheva E, Fischer P, Karpas A, . Complex translocation t(8;12;14) in a cell line derived from a child with nonendemic Burkitt-type acute lymphoblastic leukemia. Cancer Genet Cytogenet 1987;28:145–153.
   PubMed Web of Science ®Google Scholar
• Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350–4354.
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Liu J, Lombroso PJ. Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. J Biol Chem 2002;277:24274–24279.
   PubMed Web of Science ®Google Scholar
• Wu Z, Irizarry RA. Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J Comput Biol 2005;12:882–893.
   PubMed Web of Science ®Google Scholar
• Wu Z, Irizarry RA, Gentleman R, . A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. J Am Statist Assoc 2004;99:909–917.
   Web of Science ®Google Scholar
• Tan Y, Rouse J, Zhang A, . FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J 1996;15:4629–4642.
   PubMed Web of Science ®Google Scholar
• Gamberale R, Geffner JR, Sanjurjo J, . Expression of Fcgamma receptors type II (FcgammaRII) in chronic lymphocytic leukemia B cells. Blood 2003;102:2698–2699.
   PubMed Web of Science ®Google Scholar
• Camilleri-Broet S, Cassard L, Broet P, . FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. Br J Haematol 2004;124:55–62.
   PubMed Web of Science ®Google Scholar
• Gousset K, Wolkers WF, Tsvetkova NM, . Evidence for a physiological role for membrane rafts in human platelets. J Cell Physiol 2002;190:117–128.
   PubMed Web of Science ®Google Scholar
• Omidvar N, Wang EC, Brennan P, . Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. J Immunol 2006;176:2915–2923.
   PubMed Web of Science ®Google Scholar
• Morgan BP, van den Berg CW, Davies EV, . Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase. Eur J Immunol 1993;23:2841–2850.
   PubMed Web of Science ®Google Scholar
• Harder T, Scheiffele P, Verkade P, . Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol 1998;141:929–942.
   PubMed Web of Science ®Google Scholar
• Gupta N, Wollscheid B, Watts JD, . Quantitative proteomic analysis of B cell lipid rafts reveals that ezrin regulates antigen receptor-mediated lipid raft dynamics. Nat Immunol 2006;7:625–633.
   PubMed Web of Science ®Google Scholar
• Fang LW, Tai TS, Yu WN, . Phosphatidylinositide 3-kinase priming couples c-FLIP to T cell activation. J Biol Chem 2004;279:13–18.
   PubMed Web of Science ®Google Scholar
• Freedman BD, Liu QH, Somersan S, . Receptor avidity and costimulation specify the intracellular Ca2 + signaling pattern in CD4(+)CD8(+) thymocytes. J Exp Med 1999;190:943–952.
   PubMed Web of Science ®Google Scholar
• Engelke M, Engels N, Dittmann K, . Ca(2 +) signaling in antigen receptor-activated B lymphocytes. Immunol Rev 2007;218:235–246.
   PubMed Web of Science ®Google Scholar
• Vig M, Kinet JP. Calcium signaling in immune cells. Nat Immunol 2009;10:21–27.
   PubMed Web of Science ®Google Scholar
• Bishop GA, Haxhinasto SA, Stunz LL, . Antigen-specific B-lymphocyte activation. Crit Rev Immunol 2003;23:149–197.
   PubMed Web of Science ®Google Scholar
• Osterborg A, Karlsson C, Lundin J, . Strategies in the management of alemtuzumab-related side effects. Semin Oncol 2006;33:S29–S35.
   PubMed Web of Science ®Google Scholar
• Moreau T, Coles A, Wing M, . Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119(Pt 1):225–237.
   PubMed Web of Science ®Google Scholar
• Wing MG, Moreau T, Greenwood J, . Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996;98:2819–2826.
   PubMed Web of Science ®Google Scholar
• Smolewski P, Duechler M, Linke A, . Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leuk Res 2006;30:1521–9.
   PubMed Web of Science ®Google Scholar